Cost Minimization Study between Intravenous Rituximab (R-IV) vs Subcutaneous Rituximab (R-SC) in Thai Patients with Diffused Large B-CELL Lymphoma (DLBCL)- A Simulation of Electronic Health Record (E-HR) and Evidence Synthesis
Sep 1, 2018, 00:00
10.1016/j.jval.2018.07.825
https://www.valueinhealthjournal.com/article/S1098-3015(18)33182-6/fulltext
Title :
Cost Minimization Study between Intravenous Rituximab (R-IV) vs Subcutaneous Rituximab (R-SC) in Thai Patients with Diffused Large B-CELL Lymphoma (DLBCL)- A Simulation of Electronic Health Record (E-HR) and Evidence Synthesis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33182-6&doi=10.1016/j.jval.2018.07.825
First page :
Section Title :
Open access? :
No
Section Order :
56